Sep 23 2010
Signal Genetics, a privately held predictive genetic testing company focused on oncology, today announced the company will work with Array BioPharma to help push forward both companies' goals of markers for patient selection, helping bring personalized medicine and companion diagnostics to patients with multiple myeloma, a cancer of the bone marrow and antibody producing cells.
Signal Genetics' groundbreaking MyPRS™ genomic testing platform will be used to further a current research program of Array BioPharma in multiple myeloma. The MyPRS™ results will provide Array BioPharma with genetic information from patient samples in two upcoming clinical studies with Array's novel proprietary drug. This research may lead to the development of superior and personalized treatment options for myeloma patients.
"This partnership is a natural fit for Signal Genetics. In the healthcare industry there is a sprint to offer companion diagnostic platforms with truly personalized medicine. This partnership plants us, and Array BioPharma, at the forefront of innovation in the arena of personalized medicine in multiple myeloma," stated Joe Hernandez, President and Chief Executive.
Risk factors for serious inflammatory conditions in IBD patients identified